Few Patients Told About Overdiagnosis Before Screening

Share this content:
Few Patients Told About Risks of Overdiagnosis Pre-Screening
Few Patients Told About Risks of Overdiagnosis Pre-Screening

(HealthDay News) -- Few patients who are eligible for cancer screening are aware of the risks of overdiagnosis and overtreatment, according to a research letter published online Oct. 21 in JAMA Internal Medicine.

Odette Wegwarth, Ph.D., and Gerd Gigerenzer, Ph.D., from the Max Planck Institute for Human Development in Berlin, conducted a national cross-sectional survey involving 317 U.S. men and women, aged 50 to 69 years, to examine whether patients are informed by their physicians about overdiagnosis when discussing cancer screening.

The researchers found that only 9.5% of participants said that their physician had informed them about the possibility of overdiagnosis and overtreatment. Most participants (80%) wanted to be told about screening harm before undergoing testing. Thirty-four percent of the 27 participants who had not received cancer screening, but had heard about overtreatment, indicated that overtreatment was an argument against screening.

About half of participants (51%) would not start screening that resulted in more than one overtreated person per life saved due to cancer. Nearly 60% (58.9%) reported that they would continue with screening they were regularly receiving if the test resulted in 10 overtreated persons per life saved from cancer.

"Our results should prompt medical educators to improve the quality of teaching about screening and encourage medical journal editors to enforce clear reporting about overtreatment when publishing results on the effectiveness of cancer screening," the authors write.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs